Immune Checkpoint Inhibitor-induced Myositis.

Humans Immune Checkpoint Inhibitors / adverse effects Myositis / chemically induced Immunoglobulins, Intravenous / therapeutic use
Immune checkpoint inhibitors Immune-related adverse events Myasthenia gravis Myocarditis Myositis

Journal

Rheumatic diseases clinics of North America
ISSN: 1558-3163
Titre abrégé: Rheum Dis Clin North Am
Pays: United States
ID NLM: 8708093

Informations de publication

Date de publication:
May 2024
Historique:
medline: 27 4 2024
pubmed: 27 4 2024
entrez: 26 4 2024
Statut: ppublish

Résumé

Myositis induced by immune checkpoint inhibitors (ICIs) is an infrequent, potentially fatal, immune-related adverse event. It has higher incidence in patients who receive combination ICI therapy compared to monotherapy. Patients can present with clinical manifestation symptoms of myositis alone or in combination with myocarditis and/or myasthenia gravis, which significantly worsens the course and prognosis. Diagnosis can generally be made on the basis of clinical presentation, elevation of muscle enzymes, and electromyographic changes, but some patients may require a muscle biopsy. The first line of therapy is high-dose corticosteroids, followed by immunosuppression, plasmapheresis, or intravenous immunoglobulin in patients with severe disease.

Identifiants

DOI: 10.1016/j.rdc.2024.02.003 PMID: 38670726
pubmed: 38670726
pii: S0889-857X(24)00010-3
doi: 10.1016/j.rdc.2024.02.003
pii:
doi:

Substances chimiques

Immune Checkpoint Inhibitors 0
Immunoglobulins, Intravenous 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

281-290

Informations de copyright

Copyright © 2024 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Disclosure M.E. Suarez-Almazor has received consulting fees from Pfizer, Eli Lilly, Celgene, and Syneos Health in the past 12 months, unrelated to this work.

Auteurs

Athira Jayan (A)

Department of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, 1515 Holcombe Boulevard, Houston, TX 77030, USA.

Andrew L Mammen (AL)

Department of Neurology, Johns Hopkins University School of Medicine; Department of Medicine, Johns Hopkins University School of Medicine; Muscle Disease Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Building 50, Room 1146, Bethesda, MD 20892, USA.

Maria E Suarez-Almazor (ME)

Department of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, 1515 Holcombe Boulevard, Houston, TX 77030, USA; Department of Health Services Research, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA; Section of Rheumatology and Clinical Immunology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA. Electronic address: msalmazor@mdanderson.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Immune Checkpoint Inhibitor-induced Myositis.
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Antinéoplasiques › Antinéoplasiques immunologiques › Inhibiteurs de points de contrôle immunitaires › Immune Checkpoint Inhibitor-induced Myositis.
questionsmedicales.fr › Maladies du système nerveux › Maladies neuromusculaires › Maladies musculaires › Myosite › Immune Checkpoint Inhibitor-induced Myositis.
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Immunoglobulines par voie veineuse › Immune Checkpoint Inhibitor-induced Myositis.